Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma

被引：64

作者：

Hummers, LK ^{[1
]}

Wigley, FM ^{[1
]}

机构：

[1] Johns Hopkins Univ, Div Rheumatol, Baltimore, MD 21205 USA

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2003年 / 29卷 / 02期

关键词：

D O I：

10.1016/S0889-857X(03)00019-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Raynaud's phenomenon, in the setting of scleroderma, is a complex and frustrating problem, which may lead to significant morbidity. The vasospastic process is coupled with marked intrinsic vascular disease that is characterized by endothelial dysfunction, intimal proliferation, smooth muscle activation, and platelet aggregation. Management of Raynaud's in patients who have scleroderma involves consideration of this complex vascular process. An approach to therapy, including novel treatments, is presented.

引用

页码：293 / +

页数：22

共 94 条

[1]

Abraham DJ, 1997, AM J PATHOL, V151, P831

[2] THORACOSCOPIC CERVICODORSAL SYMPATHECTOMY - PRELIMINARY-RESULTS [J].

AHN, SS ;

MACHLEDER, HI ;

CONCEPCION, B ;

MOORE, WS .

JOURNAL OF VASCULAR SURGERY, 1994, 20 (04) :511-519

[3] Assessment of vascular function in systemic sclerosis -: Indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production [J].

Andersen, G ;

Mincheva-Nilsson, L ;

Kazzam, E ;

Nyberg, G ;

Klintland, N ;

Petersson, AS ;

Rantapää-Dahlqvist, S ;

Waldenström, A ;

Caidahl, K .

ARTHRITIS AND RHEUMATISM, 2002, 46 (05) :1324-1332

[4] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[5] TRIAL OF PLATELET-INHIBITING DRUG IN SCLERODERMA - DOUBLE-BLIND-STUDY WITH DIPYRIDAMOLE AND ASPIRIN [J].

BECKETT, VL ;

CONN, DL ;

FUSTER, V ;

OSMUNDSON, PJ ;

STRONG, CG ;

CHAO, EYS ;

CHESEBRO, JH ;

OFALLON, WM .

ARTHRITIS AND RHEUMATISM, 1984, 27 (10) :1137-1143

[6] Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer [J].

Berger, CC ;

Bokemeyer, C ;

Schneider, M ;

Kuczyk, MA ;

Schmoll, HJ .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) :2229-2238

[7]

Black CM, 1998, BRIT J RHEUMATOL, V37, P952

[8] IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro - Induction of adhesion molecule expression and involvement of endothelium-derived cytokines [J].

Carvalho, D ;

Savage, COS ;

Black, CM ;

Pearson, JD .

JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01) :111-119

[9] SUBJECTIVE AND OBJECTIVE ASSESSMENT OF ENALAPRIL IN PRIMARY RAYNAUDS-PHENOMENON [J].

CHALLENOR, VF ;

WALLER, DG ;

HAYWARD, RA ;

GRIFFIN, MJ ;

ROATH, OS .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) :477-480

[10] Vascular remodeling: The role of angiotensin-converting enzyme inhibitors [J].

Chrysant, SG .

AMERICAN HEART JOURNAL, 1998, 135 (02) :S21-S30

← 1 2 3 4 5 6 7 8 9 10 →